Letter to the Editor. Cell therapy for Parkinson’s disease

Jeffrey S. Schweitzer MD, PhD1,3, Todd M. Herrington MD, PhD1,3, Kwang-Soo Kim PhD2,3, and Bob S. Carter MD, PhD1,3
View More View Less
  • 1 Massachusetts General Hospital, Boston, MA
  • | 2 Molecular Neurobiology Laboratory, McLean Hospital, Belmont, MA
  • | 3 Harvard Medical School, Boston, MA
Online Publication Date:
04 Feb 2022
Page Range:
1810–1811
Volume/Issue:
Volume 136: Issue 6
DOI link:
https://doi.org/10.3171/2021.12.JNS212694
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Click here for subscription options

  • Purchase Now

    USD  $45.00

  • JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

    USD  $515.00

  • JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

    USD  $612.00
USD  $45.00
USD  $515.00
USD  $612.00
Print or Print + Online Sign in

Volume 136: Issue 6 (Jun 2022)

in Journal of Neurosurgery
Cover Journal of Neurosurgery

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Click here for subscription options

  • JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

    USD  $515.00

  • JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

    USD  $612.00
USD  $515.00
USD  $612.00
Print or Print + Online

Contributor Notes

Correspondence Jeffrey S. Schweitzer: jschweitzer1@mgh.harvard.edu.

INCLUDE WHEN CITING Published online February 4, 2022; DOI: 10.3171/2021.12.JNS212694.

Disclosures The authors report no conflict of interest.

Page Count:
2
  • 1

    Alterman RL. Cellular transplantation for Parkinson’s disease: a strategy whose time has passed. J Neurosurg. 2021;135(6):1898–1902.

  • 2

    Alterman RL. Stem cell transplantation for Parkinson disease: déjà vu all over again? Letter. Neurosurgery. 2021;88(2):E216–E217.

  • 3

    Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N Engl J Med. 2020;382(20):1926–1932.

  • 4

    Alterman RL, Tagliati M, Olanow CW. Open-label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol. 2011;70(1):5–8.

  • 5

    Jankovic J, Okun MS, Kordower JH. Stem cells: scientific and ethical quandaries of a personalized approach to Parkinson’s disease. Mov Disord. 2020;35(8):1312–1314.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Herrington TM, Schweitzer J, Henchcliffe C, Carter BS, Kim KS. Toward a personalized approach to Parkinson’s cell therapy. Mov Disord. 2020;35(11):2119–2120.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, et al. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson’s disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014;85(12):1419–1425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Osborn TM, Hallett PJ, Schumacher JM, Isacson O. Advantages and recent developments of autologous cell therapy for Parkinson’s disease patients. Front Cell Neurosci. 2020;14:58.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 1

    Alterman RL, Tagliati M, Olanow CW. Open-label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol. 2011;70(1):5–8.

  • 2

    Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med. 2010;16(6):653–661.

Metrics

All Time Past Year Past 30 Days
Abstract Views 561 560 64
Full Text Views 87 87 32
PDF Downloads 123 123 50
EPUB Downloads 0 0 0